Anzeige
Erschienen in:
23.11.2023 | Original Paper
Sebaceous carcinoma of the eyelid: demographical analysis and role of surgery in the management
Erschienen in: European Journal of Plastic Surgery | Ausgabe 6/2023
Einloggen, um Zugang zu erhaltenAbstract
Background
Eyelid sebaceous carcinoma is an uncommon aggressive cancer its capacity to cause serious harm and death underscores the significance of prompt identification and treatment. This study aims to evaluate the demographic, clinical, and pathological factors that impact the prognosis and survival of individuals with eyelid sebaceous carcinoma.
Methods
The data for this study was abstracted from the Surveillance, Epidemiology, and End Results (SEER) database from 2000–2018. The demographic and clinical data included several parameters, such as age, race, tumor grade, tumor size, surgical treatment, radiotherapy, chemotherapy, overall survival, and survival with specific treatments. The proportional hazard regression model was employed in this study to calculate hazard ratios and ascertain independent factors affecting survival outcomes. Data points with unidentified or missing values were excluded from the multivariate analysis to ensure robustness.
Results
A total 0f 903 of sebaceous carcinomas were extracted from the database. The mean age was 71.7 years and the majority (83.2%) were over 60 years old with a slight predominance of women (56.7%). Race was known for (96.6%) of cases, with White being the most dominant (86.6%) followed by Asian or Pacific Islander (10.2%). When tumor grade was known, poorly differentiated accounted for the majority (53.1%). Most cases with known tumor size were > 10 mm (44.9%). Where metastasis status was known, no metastasis was found in (99.2%). Most patients (80.2%) were treated with surgery alone. Being White and male had a better 5-year survival of 93.9% with a 95% confidence interval (C.I 95%) (C.I 95%, 61.3–99.0) and 95.3% (C.I 95%, 91.3–97.4) respectively. Multivariable analysis identified tumor size > 10 mm and age > 60 as independent risk factors for mortality (p < 0.010).
Conclusions
Our study found that old age and large tumor size are negative prognostic factors. Future research should target novel molecular targets and effective combination therapies to improve patient outcomes.
Level of evidence: Level III, Therapeutic; Diagnostic; Risk/Prognostic